Primers Patents (Class 536/24.33)
-
Patent number: 8318435Abstract: To extract and detect Bursaphelenchus xylophilus DNA without isolating Bursaphelenchus xylophilus from a piece of wood taken from a tree belonging to the genus Pinus and the like, provided are a method for extracting Bursaphelenchus xylophilus DNA from a collected piece of wood that includes Bursaphelenchus xylophilus, a LAMP primer set including primers that anneal to a specific region of Bursaphelenchus xylophilus DNA, and a method for detecting Bursaphelenchus xylophilus from a piece of wood by amplifying a DNA by a LAMP method using this primer set.Type: GrantFiled: October 23, 2008Date of Patent: November 27, 2012Assignee: Forestry and Forest Products Research InstituteInventors: Takuya Aikawa, Taisei Kikuchi, Natsumi Kanzaki
-
Patent number: 8318421Abstract: New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.Type: GrantFiled: July 11, 2011Date of Patent: November 27, 2012Assignee: Common Services AgencyInventors: Peter Simmonds, Shiu-Wan Chan, Peng Lee Yap
-
Patent number: 8318428Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: January 24, 2012Date of Patent: November 27, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid Heneine
-
Patent number: 8318686Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.Type: GrantFiled: May 21, 2004Date of Patent: November 27, 2012Assignee: Andes Biotechnologies S.A.Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio
-
Patent number: 8318422Abstract: The present invention relates to use of an antibacterial agent in the manufacture of a medicament for the treatment of osteoarthritis, more particularly for the treatment of a bacterial infection which is responsible for osteoarthritis. Also described are methods for the diagnosis of osteoarthritis through the detection of certain bacteria in an affected joint of a patient with osteoarthritis.Type: GrantFiled: June 17, 2002Date of Patent: November 27, 2012Assignee: Orthogenics ASInventor: Mohamed Raafat El-Gewely
-
Patent number: 8318429Abstract: The invention includes method of determining if a subject has a genetic predisposition to clinically diagnosed schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD).Type: GrantFiled: October 27, 2011Date of Patent: November 27, 2012Assignee: University of Louisville Research Foundation, Inc.Inventors: Mark David Brennan, D. Kay Phillips
-
Patent number: 8318432Abstract: Cross-reacting hybridization probe for detecting HIV-1 and HIV-2 nucleic acids. The probe advantageously exhibited uniformly high signal-to-noise ratios when hybridized to HIV-1 and HIV-2 target nucleic acids. The probe can be used, for example, in screening applications for detecting donated blood contaminated with either of the two analytes.Type: GrantFiled: January 21, 2010Date of Patent: November 27, 2012Assignee: Gen-Probe IncorporatedInventors: Jeffrey M. Linnen, Wen Wu
-
Publication number: 20120295251Abstract: The present invention relates to methods for the design and/or production of a probe or primer that is capable of hybridizing to a plurality of sites in a sample comprising nucleic acid. Furthermore, the present invention provides methods for detecting and amplifying nucleic acid using such a probe or primer, for example, for identification of a strain, species or genera. Probe or primer sequences are determined by reference to codon usage bias of a target nucleic acid. In addition, the present invention provides methods for determining codon distribution and/or base pair distance between codons in a nucleic acid.Type: ApplicationFiled: December 9, 2010Publication date: November 22, 2012Inventors: Murali Nayudu, Andrew Franklin, Yafei Zhang, Mark John Gibbs, Terry John Murphy, Adrian John Gibbs, Sheba Khan, Christian Samundsett
-
Patent number: 8314226Abstract: Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.Type: GrantFiled: March 29, 2005Date of Patent: November 20, 2012Assignee: The General Hospital CorporationInventors: David R. Tabatadze, Paul C. Zamecnik, Malay K. Raychowdhury, Horacio F. Cantiello
-
Patent number: 8313931Abstract: Methods for amplifying and detecting nucleic acids are described, as well as sets of 5? labeled oligonucleotides.Type: GrantFiled: September 26, 2008Date of Patent: November 20, 2012Assignee: 3M Innovative Properties CompanyInventor: Jesse D. Miller
-
Patent number: 8314220Abstract: The present invention provides methods, nucleic acids, compositions, and kits for detecting microRNA (miRNA) in samples. The methods comprise designing mRNA-specific primers, adding a polyA tail to the miRNA, and using reverse transcription and amplification to detect the miRNA. The nucleic acids, compositions, and kits typically comprise some or all of the components necessary to practice the methods of the invention.Type: GrantFiled: January 26, 2007Date of Patent: November 20, 2012Assignee: Agilent Technologies, Inc.Inventors: Rebecca L. Mullinax, Joseph A. Sorge
-
Publication number: 20120288863Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: January 4, 2011Publication date: November 15, 2012Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
-
Publication number: 20120288857Abstract: Methods and reagents for detection and analysis of nucleic acids are provided. Certain methods involves an encoding amplification in which a target sequence is associated with probe-binding sequences and optionally with indexing sequences, (2) an optional distribution step in which the product of the encoding amplification is split into multiple aliquots, and (3) a decoding and detection step in which the presence, absence, quantity, or relative amount of the target sequence in the aliquots is determined. The detection step makes use of a multifunctional “self-digesting” molecular probe comprising a primer polynucleotide and a probe oligonucleotide, linked in a 5?-5? orientation.Type: ApplicationFiled: February 3, 2012Publication date: November 15, 2012Applicant: Fluidigm CorporationInventor: Kenneth J. Livak
-
Patent number: 8309301Abstract: Primers have been isolated that are diagnostic for the detection of the white spot syndrome virus (WSSV). The primers are based on a new portion of the WSSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.Type: GrantFiled: September 21, 2011Date of Patent: November 13, 2012Assignee: E I du Pont de Nemours and CompanyInventors: Richard C. Ebersole, Jianzhong Zhang, Christian Peter Lenges, Mario W. Chen
-
Patent number: 8309529Abstract: Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient.Type: GrantFiled: April 30, 2008Date of Patent: November 13, 2012Assignee: Index Pharmaceuticals ABInventors: Asa Karlsson, Oliver Von Stein, Arezou Zargari, Nikolai Kouznetzov
-
Patent number: 8309702Abstract: The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific Plasmodium parasites and four species of malaria parasites in a human specimen, an anti-malaria measure support system, and a malaria infection-prevention/treatment system, which can contribute to practical diagnosis in a malaria endemic area. According to the present invention, using a genus-specific primer set that can detect four Plasmodium parasites that infect humans at a time, and the primer sets each specific to each of four species of Plasmodium parasites (P. falciparum, P. vivax, P. malariae, and P. ovale), the presence or absence of infection with these parasites can be detected/identified easily and rapidly.Type: GrantFiled: May 27, 2008Date of Patent: November 13, 2012Assignees: Ehime University, Otsuka Pharmaceutical Co., Ltd.Inventors: Takafumi Tsuboi, Eun-Taek Han
-
Patent number: 8309330Abstract: Methods, substrates, and systems for diagnostic sequencing are provided. Small circles of nucleic acids from about 10 bases to about 200 bases can be sequenced, for example using template dependent sequencing by synthesis. The use of small circles of nucleic acids allows for repeated sequencing of the same portions of the nucleic acid, providing for higher accuracy sequence determinations.Type: GrantFiled: February 1, 2011Date of Patent: November 13, 2012Assignee: Pacific Biosciences of California, Inc.Inventors: Kevin Travers, Geoff Otto, Stephen Turner, Cheryl Heiner, Congcong Ma
-
Patent number: 8309307Abstract: The present invention generally relates to spatial and structural genomic analysis compositions, which can be used for the mapping of chromosomes and structural analyses of chromosomal rearrangements, including the entire chromosome, as well as specific portions or regions of interest of the chromosomes. In some embodiments, multiple portions of the genome can be distinguished, for instance, using a first detection entity and a second detection entity different from the first detection entity. The detection entities may be immobilized relative to oligonucleotides, which may be selected to bind to different locations within the chromosome. For instance, the oligonucleotides may be at least substantially complementary to the chromosome, e.g., substantially complementary to a specific location of the chromosome.Type: GrantFiled: November 1, 2011Date of Patent: November 13, 2012Assignee: Agilent Technologies, Inc.Inventors: Michael Thomas Barrett, Michael P. Caren
-
Patent number: 8309308Abstract: A method for determining the amount of template nucleic acid present in a sample comprising the steps of: i) bringing into association with the sample all the components necessary for nucleic acid amplification, and all the components necessary for a bioluminescence assay for nucleic acid amplification and subsequently: ii) performing the nucleic acid amplification reaction; iii) monitoring the intensity of light output from the bioluminescence assay; and iv) determining the amount of template nucleic acid present in the sample.Type: GrantFiled: July 29, 2005Date of Patent: November 13, 2012Assignee: Lumora LimitedInventors: Laurence Carlo Tisi, James Augustus Henry Murray, Olga Gandelman, Victoria Louise Church
-
Publication number: 20120282613Abstract: The invention provides methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies. A large panel of differentially methylated regions (DMRs) have been identified. Certain of these DMRs are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA, whereas others are hypermethylated in adult female blood DNA and hypomethylated in fetal DNA. Moreover, DMRs that are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA have been shown to accurately predict a fetal aneuploidy in fetal DNA present in a maternal blood sample during pregnancy. In the methods of the invention, hypermethylated DNA is physically separated from hypomethylated DNA, preferably by methylated DNA immunoprecipitation.Type: ApplicationFiled: January 26, 2011Publication date: November 8, 2012Applicant: NIPD GENETICS LTDInventors: Philippos C. Patsalis, Elisavet A. Papageorgiou
-
Publication number: 20120283130Abstract: The present invention relates to miRNA or genes expressed in induced pluripotent stem cells, and a method for screening for induced pluripotent stem cells having functions equivalent to those of embryonic stem cells by confirming methylation of specific gene regions of induced pluripotent stem cells.Type: ApplicationFiled: January 17, 2011Publication date: November 8, 2012Inventors: Shinya Yamanaka, Michiyo Koyanagi
-
Publication number: 20120283135Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Inventors: Stephen Lindstrom, Alexander Klimov, Nancy Cox, Lamorris Loftin
-
Publication number: 20120283425Abstract: The invention is directed to isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human lipoprotein-associated phospholipase A2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.Type: ApplicationFiled: July 23, 2012Publication date: November 8, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120282593Abstract: The present invention is a kit and method for determining the virulence of an influenza virus based upon the presence or absence of leucine at position 62, arginine at position 75, arginine at position 79 and leucine at position 82 of the polymerase basic 1-F2 protein amino acid sequence.Type: ApplicationFiled: May 2, 2011Publication date: November 8, 2012Applicant: St. Jude Children's Research HospitalInventors: Jonathan A. McCullers, Julie McAuley
-
Publication number: 20120282612Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.Type: ApplicationFiled: March 4, 2010Publication date: November 8, 2012Applicants: Konica Minolta Holdings, Inc., Tokyo Institute of TechnologyInventors: Katsuko Yamashita, Keiko Fukushima
-
Patent number: 8304189Abstract: The present invention relates to the fields of biotechnology and molecular biology. In particular, the present invention relates to the construction and use of nucleic acid molecules comprising cloning sites which differ in nucleotide sequence. In particular embodiments, the present invention relates to nucleic acid molecules which contain recombination sites with different primer binding sites. These different primer binding sites may be used to sequence different ends of nucleic acid segments located between the two recombination sites.Type: GrantFiled: December 1, 2004Date of Patent: November 6, 2012Assignee: Life Technologies CorporationInventors: Jon Chesnut, Louis Leong
-
Publication number: 20120276536Abstract: A genetic polymorphism and a hair shape susceptibility gene that are related to hair shape, and a method for determining the genetic susceptibility to hair shape in individual test subjects are provided. Disclosed is a hair shape susceptibility gene, which overlaps with a haplotype block in in the 11q12.2 to 11q13.2 region (D11S4191 and D11S987) of human chromosome 11 and comprises a portion or the entirety of the base sequence of the haplotype block, wherein the haplotype block is determined by a linkage disequilibrium analysis conducted on a single nucleotide polymorphism (SNP) marker whose allele frequency differs statistically significantly between a group having a curly hair trait and a group having a non-curly hair trait, and consists of a base sequence set forth in any one of SEQ ID NO: 1 to NO: 5.Type: ApplicationFiled: October 5, 2010Publication date: November 1, 2012Applicant: Kao CorporationInventors: Hiroyuki Taguchi, Hiroshi Yoshida, Chie Fuse, Tadao Arinami
-
Publication number: 20120276535Abstract: The invention relates to a method for the diagnosis of limbal stem cell deficiency (LSCD) in a subject, based on detecting or quantifying the expression of the MUC5AC gene in a cornea sample from said subject.Type: ApplicationFiled: September 20, 2010Publication date: November 1, 2012Applicant: BIOFTALMIK, S.L.Inventors: Iker Garcia Jimenez, Nerea Gonzalez Fernandez, Javier Soria Esponera, Arantxa Acera Osa, Tatiana Suárez Cortés
-
Publication number: 20120276528Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 27, 2011Publication date: November 1, 2012Applicant: CELERA CORPORATIONInventors: Michele CARGILL, Hongjin HUANG
-
Publication number: 20120277281Abstract: The invention pertains to a RNA molecule transcribed form a long terminal repeat (LTR) sequence, comprising a sequence encoding a gene, such as CSF1R, and a sequence that is at least in part found in the LTR, in particular for detecting cancer in a subject.Type: ApplicationFiled: June 21, 2010Publication date: November 1, 2012Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Stephan Mathas, Björn Lamprecht, Bernd Dörken, Constanze Bonifer
-
Publication number: 20120277999Abstract: The invention relates to predicting or determining risk of a hematopoietic cell transplant (HCT) from a donor to induce Graft vs. Host Disease (GVHD) in a HCT recipient; to classifying HCT from a candidate donor according to the risk of inducing GVHD in a HCT recipient; and to organizational constructs (e.g., databases) and methods of producing organizational constructs (e.g., databases) in which HCT of one or more candidate donors is classified or scored according to risk of inducing GVHD in a HCT recipient. The invention also relates to kits and arrays useful for predicting or determining risk of HCT from a candidate donor to induce GVHD in a HCT recipient, and for classifying or scoring such donors according to risk of inducing GVHD in a HCT recipient.Type: ApplicationFiled: October 31, 2011Publication date: November 1, 2012Applicant: PBD BIODIAGNOSTICS, LLCInventors: Roland Somogyi, Larry David Greller
-
Publication number: 20120276524Abstract: The present invention relates to a genotyping method, and more particularly to an ID sequence, which is assigned to each genotype, and a multiplex genotyping method which uses the ID sequence. When pyrosequencing is performed using the ID sequence, a unique and simple pyrogram can be obtained for each genotype. Thus, the use of the ID sequence makes it possible to genotype viral genes, disease genes, bacterial genes and identification genes in a simple and efficient manner. In addition, a genotyping primer of the invention can be used in various genotyping methods which are performed using dispensation orders and sequencing methods.Type: ApplicationFiled: November 15, 2010Publication date: November 1, 2012Applicant: GENOMICTREE, INC.Inventors: Sung Whan An, Myung Sok Oh
-
Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
Patent number: 8298792Abstract: This invention provides a process for sequencing single-stranded DNA employing modified nucleotides.Type: GrantFiled: February 8, 2011Date of Patent: October 30, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jingyue Ju, Dae Hyun Kim, Lanrong Bi, Qinglin Meng, Xiaoxu Li -
Patent number: 8298767Abstract: Aspects of the present invention are drawn to processes for moving a region of interest in a polynucleotide from a first position to a second position with regard to a domain within the polynucleotide, also referred to as a “reflex method”. In certain embodiments, the reflex method results in moving a region of interest into functional proximity to specific domain elements present in the polynucleotide (e.g., primer sites and/or MID). Compositions, kits and systems that find use in carrying out the reflex processes described herein are also provided.Type: GrantFiled: August 13, 2010Date of Patent: October 30, 2012Assignee: Population Genetics Technologies LtdInventors: Sydney Brenner, Gi Mikawa, Robert Osborne, Andrew Slatter
-
Patent number: 8299235Abstract: The invention is directed to compositions for gene silencing by providing short RNA molecules to cells.Type: GrantFiled: December 17, 2004Date of Patent: October 30, 2012Assignee: Plant Bioscience LimitedInventors: David Charles Baulcombe, Andrew John Hamilton
-
Publication number: 20120270948Abstract: Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and/or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided.Type: ApplicationFiled: January 13, 2012Publication date: October 25, 2012Inventors: Sebastian Raimundo, Ulrich Zanger
-
Publication number: 20120270211Abstract: A chemically-enhanced primer is provided comprising a negatively charged moiety (NCM), an oligonucleotide sequence having a) non-nuclease resistant inter-nucleotide linkages or b) at least one nuclease resistance inter-nucleotide linkage. The chemically-enhanced primer can be used for sequencing and fragment analysis. Methods for synthesizing the chemically-enhanced primer as well as a method of preparing DNA for sequencing, a method of sequencing DNA, and kits containing the chemically-enhanced primer are also provided. The method of sequencing DNA can comprise contacting amplification reaction products with the composition wherein excess amplification primer is degraded by the nuclease and the chemically-enhanced primer is essentially non-degraded.Type: ApplicationFiled: February 15, 2012Publication date: October 25, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Linda LEE, Sam WOO, Peter MA
-
Patent number: 8293502Abstract: Compositions and methods of use are disclosed for clonally amplifying target polynucleotide sequences in solution and attaching the amplicons to a surface by activation of a masked binding moiety. In an embodiment, the amplicons comprise the masked binding moiety and the surface comprises a binding partner of the binding moiety. Upon activation of the binding moiety, the amplicons bind to the binding partner on the surface. In a non-limiting example, the masked binding moiety is caged biotin or caged fluorescein, while the corresponding binding partner is avidin or an anti-fluorescein antibody.Type: GrantFiled: April 14, 2011Date of Patent: October 23, 2012Assignee: Applied Biosystems, LLCInventor: Benjamin Schroeder
-
Patent number: 8293466Abstract: Primers have been isolated that are diagnostic for the detection of the white spot syndrome virus (WSSV). The primers are based on a new portion of the WSSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.Type: GrantFiled: September 21, 2011Date of Patent: October 23, 2012Assignee: E I du Pont de Nemours and CompanyInventors: Richard C. Ebersole, Jianzhong Zhang, Christian Peter Lenges, Mario W. Chen
-
Publication number: 20120264130Abstract: A novel transgenic corn event designated MIR162 is disclosed. The invention relates to nucleic acids that are unique to event MIR162 and to methods for detecting the presence of the MIR162 event based on DNA sequences of the recombinant constructs inserted into the corn genome that resulted in the MIR162 event and of genomic sequences flanking the insertion site. The invention further relates to corn plants comprising the transgenic genotype of MIR162 and to methods for producing a corn plant by crossing a corn plant comprising the MIR162 genotype with itself or another corn variety. Seeds of corn plants comprising the MIR162 genotype are also objects of the present invention. The invention also relates to methods of controlling insects using MIR162 corn plants.Type: ApplicationFiled: June 27, 2012Publication date: October 18, 2012Applicant: SYNGENTA PARTICIPATIONS AGInventors: Nykoll Long, Jeff Bottoms, Moez Meghji, Hope Hart, Qiudeng Que, Derrick Pulliam
-
Publication number: 20120264122Abstract: Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample.Type: ApplicationFiled: April 30, 2012Publication date: October 18, 2012Applicant: GEN-PROBE INCORPORATEDInventors: Steven T. BRENTANO, Dmitry LYAKHOV, James D. CARLSON, Norman C. NELSON, Lyle J. ARNOLD, JR.
-
Publication number: 20120266325Abstract: Provided are a plant stress tolerance related protein GmSIK1 and encoding gene and use thereof. The GmSIK1 protein has the amino acid sequence as shown in SEQ ID NO: 2. The transgenic plant with enhanced stress tolerance such as drought tolerance and/or salt tolerance can be obtained from introducing the encoding gene of GmSIK1 protein into plant cell.Type: ApplicationFiled: October 15, 2010Publication date: October 18, 2012Inventors: Shouyi Chen, Jinsong Zhang, Peng Liu, Wanke Zhang, Sijie He, Qing Lin
-
Publication number: 20120264126Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.Type: ApplicationFiled: November 17, 2010Publication date: October 18, 2012Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Erik P. Johnson, Dale A. Schwab
-
Publication number: 20120266261Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.Type: ApplicationFiled: March 16, 2012Publication date: October 18, 2012Inventors: Philippe Despres, Vincent Deubel, Jean-Louis Guenet, Marie-Thérèse Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasséli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
-
Patent number: 8288523Abstract: The present invention provides compositions, kits and methods for rapid identification and quantification of bacteria by molecular mass and base composition analysis.Type: GrantFiled: March 7, 2007Date of Patent: October 16, 2012Assignee: Ibis Biosciences, Inc.Inventors: Rangarajan Sampath, Thomas A. Hall, David J. Ecker, Lawrence Blyn
-
Patent number: 8288093Abstract: The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of human cytomegalovirus nucleic acid in a sample.Type: GrantFiled: April 8, 2008Date of Patent: October 16, 2012Assignee: Third Wave Technologies, Inc.Inventors: Jeff G. Hall, Victor I. Lyamichev, Andrea L. Mast, Mary Ann D. Brow
-
Patent number: 8288522Abstract: Methods for detecting and optionally quantitating one or more target nucleic acids are provided, in which a surrogate nucleic acid is captured to each target nucleic acid, amplified, and detected. Compositions, kit, and systems related to the methods are also described.Type: GrantFiled: August 10, 2011Date of Patent: October 16, 2012Assignee: Affymetrix, Inc.Inventors: Yuling Luo, Son Bui
-
Patent number: 8288524Abstract: A highly specific assay can be used for the detection of bacteremia in the clinical setting. The ubiquitous background endogenous DNA present in all PCR reagents is eliminated using a restriction endonuclease digestion. Universal primers for eubacteria are used for detection, and specific primers or probes for bacterial species can be used for identification of species.Type: GrantFiled: August 3, 2010Date of Patent: October 16, 2012Assignee: The Johns Hopkins UniversityInventors: Richard E. Rothman, Maulik D. Majmudar, Charlotte A. Gaydos
-
Patent number: 8288095Abstract: The invention relates to methods and systems for sequencing and constructing a high resolution physical map of a polynucleotide. In accordance with the invention, nucleotide sequences are determined at the ends of restriction fragments produced by a plurality of digestions with a plurality of combinations of restriction endonucleases so that a pair of nucleotide sequences is obtained for each restriction fragment. A physical map of the polynucleotide is constructed by ordering the pairs of sequences by matching the identical sequences among the pairs.Type: GrantFiled: September 11, 2009Date of Patent: October 16, 2012Assignee: Illumina, Inc.Inventor: Stephen C. Macevicz
-
Publication number: 20120258887Abstract: The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins that includes an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome.Type: ApplicationFiled: January 9, 2012Publication date: October 11, 2012Applicant: CENTRE FOR ADDICTION AND MENTAL HEALTHInventors: John B. Vincent, Muhammad Ayub